Adjuvanted influenza virus vaccine inactivated trivalent - Vaxine

Drug Profile

Adjuvanted influenza virus vaccine inactivated trivalent - Vaxine

Alternative Names: Adjuvanted seasonal 2008 trivalent inactivated influenza vaccine - Vaxine

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxine
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 27 Sep 2017 No recent reports on development identified - Phase-I/II for Influenza virus infections (Prevention) in Australia (IM)
  • 16 Sep 2015 Vaxine completes a phase I/II trial for Influenza virus infections (Prevention, In elderly subjects and patients with chronic diseases) in Australia (ACTRN12608000364370)
  • 20 Apr 2010 Clinical development of the Adjuvanted seasonal influenza vaccine is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top